
Drug Industry Daily: Subscribe Now!
Drug Industry Daily
Compliance — and business success — are rooted in an understanding of the top pharma and regulatory developments that come every single day.
You need to know about and respond to the regulations, guidances and policies coming from the FDA and international regulators; advances in drug research and development; mergers, acquisitions and other deals that change the face of the industry; insights from key opinion leaders; best practices in GMP compliance; and so much more.
You’ll get all of this news and understanding in Drug Industry Daily.
Merged with Drug GMP Report and free daily briefing, Drug Daily Bulletin, the upgraded Drug Industry Daily is all the news you’ve come to rely on with analysis of developing trends and deeper dives into specific areas of concern for drugmakers.
It’s quality you can rely on, as Drug Industry Daily is reported and written by FDAnews’ team of experienced drug industry journalists and subject matter experts.
The content includes columns to keep you apprised of legislative and regulatory developments and FDA-held meetings, as well as timely content from FDAnews management reports and webinars. You can’t afford to go without valuable insights into:
- Breaking news on COVID-19 (including the launch of new trials; the approvals of vaccines and treatments; and supply deals that the U.S., EC and other governments have struck with drugmakers)
- Regulatory developments and new regulatory policies by the FDA and other regulatory agency guidances
- Pharma company mergers, especially when a company is getting into a new therapeutic area
- Analyses of developments in the pharma industry
- Developments in drug pricing and drug labeling policies
- FDA budgets and spending, including approvals and proposals by Congress and the president
- FDA management and structure
- Quality and GMP regulatory policies and developments in the industry
- Patent exclusivity lawsuit rulings and developments
- FDA inspection policies and schedules
- FDA enforcement actions
- Global enforcement trends
- Pharmacovigilance developments in the EU and elsewhere
- Recalls
Get ahead — and stay compliant — with the major breaking pharma and regulatory developments and analysis in the upgraded Drug Industry Daily.
Start your single-user one-year subscription (250 issues) DID for only $1,695.
Also available: Take advantage of our multi-user and site licenses of Drug Industry Daily, so you’ll have the most-informed workforce! Contact Will Tuttle, Business Development Representative at wtuttle@fdanews.com or +1 612.216.2948 to receive a custom quote.
We’re confident the value DID provides you will pay for itself many times over. If you disagree, there’s our No-Risk, 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Drug Industry Daily, you may cancel your subscription and receive a full refund. No questions asked.